WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA;“ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment ...